The Medicare GLP-1 Bridge is a CMS demonstration program that provides eligible Medicare Part D beneficiaries with access to certain GLP-1 weight management medications for $50 per month
Injections act like a shortcut, not a solution
That is not a regimen the label describes
"For pharmaceutical executives, the lesson is clear: success in obesity will depend not only on science but also on vigilance, payer alignment, cultural reframing, and equitable access." But to understand this moment, it is important to trace the evolution of obesity drugs, why most failed, and what lessons the industry must carry forward
Polyethylene glycol (PEG) is one of the rare synthetic polymers approved by the FDA for in vivo injection, which has low relative molecular weight polydispersity, good aqueous phase and organic solubility, and is widely used in the modification of protein drugs